Abstract P3-11-11: Dedicated breast PET (dbPET) a unique functional new tool to accurate quantify response to neoadjuvant therapy in breast cancer

Background: Breast cancer is one of the most common cancers in women. Approximately 232,670 new cases of breast cancer (14% of all new cancer cases) and 40,000 breast cancer deaths (6,8% of all cancer deaths) are expected to occur among US women in 2014. Since 1990, breast cancer death rates have dropped by 34%. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment Recently, the MAMmography with Molecular Imaging (MAMMI) dedicated breast PET (dbPET) has emerged as an additional imaging tool for breast cancer diagnosis, clarification of complex lesions and therapy follow-up. This study is aimed to determine whether correlations exist between physiological images with 18FDG of pre, post-2-cycles and post Neoadjuvant Chemotherapy, with a predictive value of response. Methods: Twenty-five patients, and three scan points: pre, 2 cycle and post Neoadjuvant Chemotherapy were included in this analysis A prone position high-resolution dedicated breast PET (MAMMI-dbPET) was performed 60 min after administration of 90-120 MBq of 18F-FDG. Maximum standardized uptake value (SUVmax) quantification, volume characterization, positioning in all three space-axes, distances to reference points (proximal breast limit, nipple areola complex) were registered. Results: When treatment was successful, a significant difference was found between pre and post neoadyuvant chemotherapy status and the SUVmax (p Conclusions: dbPET MAMMI has proven to be an excellent tool for quantification, 3D spatial localization and monitoring of neoadjuvant therapy, showing, thanks to its functional nature, earlier and better precision and accuracy than conventional techniques (MRI). Post 2-cycle and Post Neodayuvant Chemotherapy breast cancer tumors consistently display lower 18FDG uptake than pre treatment tumors when treatment is successful. This data suggest that SUVmax measurements of 18FDG-dedicated breast PET can provide valuable information about therapy efficiency. Such an association might be of relevant importance to treatment continuity or adjustement. Citation Format: Michel Herranz, Ines Dominguez, Alvaro Ruibal, Elena Brozos, Sze Yiun Teo, Carmela Rodriguez, Jasper Chaal, Maria Teresa Curiel, Juan Cueva, Beatriz Fernandez, Gabriel G Pavon, Marielle Fortier, Rafael Lopez. Dedicated breast PET (dbPET) a unique functional new tool to accurate quantify response to neoadjuvant therapy in breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-11.